Medical World News® Deep Dive: Expert Talks FDA Approval of Amivantamab to Treat NSCLC With EGFR Exon 20 Insertion Mutations

Video

Joshua Sabari, MD, discussed the approval of amivantiamab as therapy for patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations.

In this episode of Deep Dive from the Medical World News® broadcast, CancerNetwork® spoke with Joshua Sabari, MD, of NYU Langone Health Perlmutter Cancer Center, to learn more about amivantamab (Rybrevant) as a treatment for non–small cell lung cancer with EGFR exon 20 insertion mutations.

Sabari detailed the challenges of treating tumors with this mutation and compared amivantamab with the other systemic therapy options in this setting. He also discusses what the future might have in store for amivantamab in this specific disease.

Recent Videos
The 2 main pafolacianine components, a folate analog and a dye, are commonly used in other medical applications.
An intravenous infusion administered prior to surgery enables treatment to occur in a normal time frame without the need for additional procedural time.
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
Increased use of systemic therapies, particularly among patients with high-risk node-negative NSCLC, were observed following radiotherapy.
Interest in novel therapies to improve outcomes initiated an investigation of the use of immunotherapy in early-stage non-small cell lung cancer.
Higher, durable rates of response to frontline therapy are needed to potentially improve long-term survival among patients with non–small cell lung cancer.
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Related Content